Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 291,500 shares, an increase of 140.3% from the October 31st total of 121,300 shares. Approximately 11.5% of the company’s shares are sold short. Based on an average daily volume of 266,300 shares, the short-interest ratio is presently 1.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Hedge Funds Weigh In On Aligos Therapeutics

Large investors have recently modified their holdings of the company. Armistice Capital LLC increased its stake in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Stock Up 7.7 %

Shares of NASDAQ ALGS opened at $22.99 on Friday. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $30.00. The firm has a market cap of $82.49 million, a PE ratio of -1.73 and a beta of 2.11. The company’s fifty day simple moving average is $11.50 and its 200 day simple moving average is $12.61.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The firm had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the firm earned ($10.25) earnings per share. On average, equities analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).